The BRAF Inhibitors market is expected to grow significantly in the coming years. This is due to the increasing number of patients being diagnosed with cancer, rise in biomarker testing rates, the ...
The following is a summary of “Anakinra improves retention rate of targeted treatments in Erdheim-Chester disease,” published ...
Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX® ) and mFOLFOX6 ...
Pfizer’s BREAKWATER trial of Braftovi combo regimen demonstrates improved response in patients with BRAF V600E-mutant metastatic colorectal cancer: New York Tuesday, January 28, ...
Class 2 MAP2K1 mutants occasionally but not universally co-occur with other MAPK driver mutations and can be effectively inhibited with FDA-approved MEK inhibitors. 13 In our AACR GENIE cohort, ...
This is the fourth FDA-approved indication for Braftovi, coming after it was cleared in combination with MEK Inhibitor Mektovi (binimetinib) for BRAF-mutated melanoma and non-small cell lung ...
It also developed MEK inhibitor Cotellic (cobimetinib) – sold by Roche for BRAF-positive melanoma – and Daiichi Sankyo-partnered hypertension drug Minnebro (esaxerenone). There are some 7,000 ...
After hours: January 30 at 4:09:50 PM EST Loading Chart for SWTX ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback